On January 21, 2025, the Company filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (“SEC”) announcing board and stockholder approval of a 1-for-15 reverse stock split (the “Reverse Stock Split”) of the C...
We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K dated September 23, 2022, as amended by the Current Report Form 8-K/A Amendment No.1 on October 6, 2022 and we agree with the statements concer...